We studied the distribution of the enzymes that are involved in the post-translational alpha-amidation of tegulatory peptides in human endocrine pancreas, using immunocytochemical methods for light and electron miaoscopy. Immunoreactivity for the two enzymes h l d , peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidylalpha-hydroxyglycine alpha-amidating lyase (PAL), was located in the periphery of the islets of Langerhans and in ductal endocrine cells. Staining of reverse-face serial sections demonstrated that these immunoreactivities co-localize with glucagon but not with pancreatic polypeptide (PP), insulin, or somatostatin. Double immunogold staining for electron microscopy amfiimed the previous results and revealed a differ-ent localization for each enzyme inside the secretory granule: PHM is present in the central core of the glucagoncontaining granules, whereas PAL is predominantly located near the granule membrane. The existence of an amidated peptide, GLP1, in the A-ells explains the presence of peptidylglycine alpha-amidating monooxygenase enzymes (PAM) in these cells. The absence of the enzymes in the PPcells raises the possibility that a different form of amidating enzyme may be involved in the post-translational processing of this peptide. ( JHistochem Cytochem 41:375-380, 1993) 
Introduction
Bioactive peptides frequently bear a carboxy-terminal alpha-amide as the result of a post-translational process essential for biological activity (May et al., 1990) . The enzymes responsible for this modification are collectively known as peptidyl-glycine alpha-amidating monooxygenase or PAM (E.C. 1.14.17.3).
Human PAM precursor has been cloned from thyroid carcinoma cells (Glauder et al., 1990) . As in other mammalian species, the gene encodes two proteins, both of them involved in the alphaamidation of peptides: peptidylglycine alpha-hydroxylating monooxygenase (PHM) catalyzes the conversion of glycine-extended pro-peptides into peptidyl-alpha-hydroxyglycine intermediates. The second step is carried out by the peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL) .
PAM enzymatic activity has been biochemically described in a variety of endocrine (e.g., Birnbaum et al., 1989a; Markosian et Sheldrick and Flint, 1989; Katopodis and May, 1988; Glembotski, 1985) and non-endocrine (e.g., Rhodes et al., 1990; Birnbaum et al., 1989b; Von Zastrow et al., 1986; Eipper et al., 1985; Mains et al., 1985) tissues. Precise immunocytochemical localization of the involved cells has been carried out only in heart , pituitary (May et al., 1990) , and central nervous system (Schafer et al., 1992; Rhodes et al., 1990) .
There is biochemical evidence of PAM activity in the islets of Langerhans of fish and rats: a cytochrome b561 has been described in the membrane of the secretory granules as a component of the ascorbate-dependent PAM system in the anglerfish (Mackin et al., 1986) and, in the same animal, the islet secretory granule lysates show PAM activity with the same requirements as its mammalian counterpart: copper, ascorbate, and molecular oxygen (Mackin et al., 1987) . The presence of the amidating enzymes in rat pancreatic islet culture (Scharfmann et al., 1988) , as well as the expression of PAM mRNA (Maltese et al., 1989) , has also been reported.
Although these studies show PAM activity to occur in many tissues, there is little morphological evidence about which cells contain the enzymes, whether the enzymes act in vivo as a single bifunctional protein or are cleaved to act separately, whether they act inside the secretory granules, as has been claimed Tozawa et al., 1990; Braas et al., 1989; May et al., 1988) , and whether or not they are membrane bound. The present study uses human pancreas as a model to investigate by immunocytochemical methods at light and electron microscopic levels whether PAM enzymes are present in human tissues, which cells express PAM enzymes, and their intracellular localization and relative distributions.
Materials and Methods
Antisera. Two antisera raised against synthetic peptides of the PAM molecule were used. As shown in Figure 1 , one of them (CC) was raised to a portion of the pre-pro-enzyme coding for PHM activity, and the other (PAL2) was raised to a portion of the precursor coding for PAL activity. Both peptides were synthesized by Applied Biosystems (Torrance, CA) by standard solid-phase methodology, and were purified by HPLC to greater than 95% purity. The sequences of the peptides are: CC = CVFTGEGRTEVTHIGGTSSDEMC (human PAM 288-310 with a Val for Ala substitution at position 11 within the peptide) PAL2 = IFHRGDHVWDGNSFDSKFVY (human PAM 527-546).
Polyclonal antibodies to each PAM peptide were generated in rabbits by multiple subcutaneous injections of peptide (1 mg) coupled to keyhole limpet hemocyanin (1 mg) by glutaraldehyde (0.25% in 1 ml total volume) overnight at 4-C. The initial injection was given as a suspension of coupled peptide and carrier in complete Freund's adjuvant, and after challenge injections were given as suspension in incomplete Freund's. Rabbits were bled before immunization and approximately 2 weeks after each challenge. Serum (10 ml) was collected and stored at 4'C. Antibody titers were tested in a 96-well plate ELISA method using solid-phase peptide (50 ng/well). Antisera had titers of at least 1:800-1:1600. When tested on rat pituitary sections these antibodies gave a similar staining pattern to that previously observed by May et al. (1990) in the same organ.
To localize pancreatic hormones, monoclonal antibodies against glucagon, somatostatin, and insulin (NovoClone; Bagsvaed, Denmark) and a polyclonal antiserum to pancreatic polypeptide (ICN; Lisle, IL) were used. The specificity of the antisera was tested using absorption controls with homologous and heterologous antigens obtained from Sigma (St Louis, MO). the Department of Pathology of the Clinica Universitaria de Navarra and the Department of Histochemistry of the Hammersmith Hospital.
Tissues
Light Microscopy. Three pancreatic specimens fixed in buffered formalin and embedded in paraffin were used for the study at the light microscopic level. Serial reverse-face sections (Osamura et al., 1980) were used to show the coexistence of immunoreactivities in the same cells. After dewaxing, immunocytochemical staining was performed with the avidin-biotin method (Hsu et al., 1981) . Sections were pre-treated with 0.3% hydrogen peroxide in methanol for 30 min and with normal swine serum (NP-1, 1:20; University of Navarra) for 30 min. After an overnight incubation at 4'C with the primary antisera, sections were incubated for 30 min with biotinylated secondary immunoglobulins (biotinylated anti-rabbit or antimouse IgG) (Dakopatts; Glostmp, Denmark), followed by a third incubation with avidin-biotin-peroxidase complexes (Dakopatts) for 30 min. After each incubation, sections were rinsed with Xis-HC1-buffered saline (TBS, 0.05 M, pH 7.36; 0.55 M NaCI). The sections were then washed in Tris-HC1 buffer (0.05 M, pH 7.36) and the peroxidase activity revealed by incubation in a solution of 0.03% 3,Y-diaminobenzidine tetrahydrochloride (D-5637; Sigma) and 0.006% H202 in Tris-HCI. The sections were counterstained with hematoxylin.
To test the specificity of the reagents, the following controls were done on each specimen: (a) omission of the primary antibodies; (b) application of primary antibodies previously absorbed, by incubation overnight at 4"C, with 1 to 10 nmol of the synthetic peptide antigens per ml of optimally diluted antiserum; and (c) staining using DAB-HzOz alone. To study the distribution ofthe gold particles within the secretory granules, a statistical analysis was performed. Ten secretory granules per antibody were chosen and in each granule the distances to the center of three randomly selected gold particles were measured and Student's t-test was applied to these data.
Light Microscopy
The antibodies against PHM and PAL strongly stained cells in the periphery of the islets of Langerhans, isolated cells in the pancreatic parenchyma, and some ductal cells (Figure 2) . The study of reverseface serial sections showed that all the glucagon-positive cells were also immunoreactive for both PAM antibodies (Figure 3) . In contrast, cells immunoreactive for insulin ( Figure 4) . somatostatin (Figure 5) , and PP ( Figure 6) were negative for the PHM and PAL antibodies used. Cells positive for both antisera were numerous in the extralobular ducts and occasionally some of them appeared in the intralobular ductules. None of them showed co-localization with the pancreatic hormones. When the specificity controls were done no staining was observed.
Electron Microscopy
The double immunogold method showed that the immunoreactivity for the amidating enzymes is located inside the secretory granules coexisting with glucagon (Figures 7-10) . Although PHM labeling was homogeneously distributed within the granular core ( Figure  7) , PAL immunoreactivity was located predominantly near the granular membrane (Figure 8 ).
The immunogold technique clearly showed that in glucagoncontaining granules both the PHM and the hormone are located in the central region of the granule but not in the characteristic peripheral halo (Figure 9 ).
As expected from the light microscopic results, granules containing peptides other than glucagon were negative for PAM antibodies at the electron microscopic level (Figures 9 and 10) .
No immunoreactivity was observed in the Golgi complex or in the endoplasmic reticulum of the endocrine cells.
The statistical analysis showed that no significant difference between the distributions of PHM-and glucagon-related gold particles could be found. On the other hand, there was a very significant difference (p<O.Ol) when comparisons were made with the PALbound particles.
Discussion
This study shows that PAM enzymes are present in human pancreas in A-cells and in some endocrine ductal cells but not in PP-, p-, or D-cells, or in other pancreatic structures, and that the two enzymes have different relative distributions within secretory granules.
The presence of amidating enzymes in A-cells and their absence from pand D-cells seems to be consistent with the pattern of amidation of the main pancreatic peptides. Although glucagon is not an amidated peptide, GLP1, a peptide co-expressed by the same gene and known to be present in the same granules, possesses a carboxy-terminal amide group (Orskov et al., 1989) . Conversely, insulin and somatostatin are not terminally amidated and therefore, assuming that no other amidated peptides are produced, the presence of PAM-related enzymes is not expected. It is more difficult to explain the absence of PAM immunoreactivity from PP-cells, as all the members of the PP family including pancreatic polypeptide, neuropeptide Y, and peptide W, are amidated (Takeuchi and Yamada, 1985; Minth et al., 1984; Tatemoto, 1982) . Moreover, it has been observed that when PAM-containing cells were transfected with the gene encoding the PP precursor the amidated form of the hormone was produced (Ekeuchi et al., 1991) , demonstrating the ability of PAM to amidate PP. Our results suggest that in the case of the pancreatic PP-containing cells a different amidating enzyme is involved. In fact, some structural and physiological changes in amidating enzymes have been observed in several tissues (Stoffers et al., 1991; Gilligan et al., 1989) , and in the case of gastrin the amidation process is different in pituitary and antrum (Dickinson and Yamada, 1991) .
The presence of PAM-positive duct cells could be explained by the existence in this location of other amidated peptides or proteins (Vaillant et al., 1990) or by the presence of totipotent stem cells in different developmental stages (Kimura et al., 1990; Rosenberg et al., 1990) .
The study carried out at the electron microscopic level confirms the light microscopic observations and reveals a different distribution for the two enzymes involved: PHM immunoreactivity appears within the granule contents, whereas PAL is near the membrane. This is in agreement with the structure of the PAM precursor gene (see Figure 1 ). PHM is encoded in the part corresponding to the NHz-terminal region of the protein, the middle third contains PAL. , and the COOH-terminal fragment encodes a transmembrane domain and a hydrophilic tail, which could possibly insert on the cytoplasmic face of the granular membrane (Perkins et al., 1990; Eipper et al., 1987 ). An optional exon containing a cleavage (Lys-Lys) site is present between the PHM and the PAL regions (Milgram et al., 1992; Glauder et al., 1990) , generating two different situations: (a) a long membrane-anchored protein containing both enzymes linked together when the cleavage site is eliminated, or (b) two shorter separate proteins when the exon is not removed. In the second case, the NHz-terminal region containing the PHM could appear freely in the contents of the granule and PAL would remain attached to the membrane by the transmembrane domain. In fact, when the expression of the amidating enzymes was studied in PALtransfected cells, the enzymatic activity was associated with the membrane . Our results in human pancreas support the second contention because PHM appears free in the granular contents, but they do not exclude the possibility that some of the uncleavable molecule can also be produced.
It has been observed that the ratio between free and membranebound PAM activity seems to be tissue specific (Braas et al., 1989; May et al. 1988) , and probably the ultrastructural distribution of the enzymes in other organs could be quite different.
The absence of immunoreactivity for the enzymes in the Golgi complex and in the endoplasmic reticulum may also be relevant. It suggests that the PAM precursor molecule may not be cleaved until after formation of the secretory granules, at which point the epitopes recognized by our antibodies are unmasked.
In summary, PAM immunoreactivity has been located in the secretory granules of human pancreatic A-cells. The PHM and PAL molecules have a different distribution, suggesting cleavage of the molecule and membrane binding of PAL. The lack of PHMlPAL immunoreactivity from some islet cells known to produce amidated peptides suggests that other peptide-amidating enzyme systems exist, and this merits further investigation.
